The purpose of this study is to prospectively validate the new risk model, based on minimal residual disease (MRD) response level and oncogenetic status by comparing historical results of GRAALL-2005 with those of GRAALL-2014 in an identical population of patients (Philadelphia chromosome negative, B lineage ALL, aged 18 to 59 years old).
Study Type
OBSERVATIONAL
Enrollment
500
Hématologie Adulte, Saint Louis hospital
Paris, France
RECRUITINGDisease free survival (DFS)
Time frame: 4 years
Cumulative incidence of relapse (CIR)
Time frame: 4 years
non relapse mortality (NMR)
Time frame: 4 years
Overall survival
Time frame: 4 years
Cumulative incidence of relapse (CIR) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)
Time frame: 4 years
overall survival after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)
Time frame: 4 years
Non relapse mortality (NRM) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)
Time frame: 4 years
Disease free survival (DFS) after censoring at allo-stem cell transplantation (SCT) in first complete remission (CR)
Time frame: 4 years
Minimal residual disease (MRD)
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.